Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240616 · ClinicalTrials.gov registry record
Nicotinic Modulation of the Default Network of Resting Brain Function
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 43
- Enrollment target
NCT01240616: Completed study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01240616 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01240616 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Background: \- A brain circuit called the default network is the brain circuit that is active when the brain is at rest; that is, when individuals are not concentrating on specific tasks. Previous research has shown that the default network functions differently in people with schizophrenia and Alzheimer s disease, and may contribute to the problems with memory and concentration that can affect people who have these conditions. Studies have also shown that nicotine affects the default network, but more research is needed on the ways in which nicotinic receptors may change activity in these regions and thereby affect individuals ability to concentrate on specific tasks. Objectives: \- To determine whether and how nicotine and mecamylamine, a drug that blocks nicotinic receptors, affect the default network in nonsmokers in ways that improve thinking and concentration. Eligibility: * Healthy, right-handed volunteers between 21 and 50 years of age. * Volunteers must not have used any kind of tobacco product in the past 2 years. Design: * This study involves an initial screening visit, a training visit, and three testing visits. * Participants will be screened with a medical history and physical examination, as well as blood and urine samples and questions about smoking history. * Participants will have an initial training session to practice the tasks that will be done during magnetic resonance imaging scans at the testing visits. These tasks will test participants concentration and memory. * Participants will have three test sessions with the following combinations of study drugs: (1) a nicotine patch and a placebo capsule, (2) a placebo patch and a capsule of mecamylamine, or (3) a placebo patch and capsule. Different combinations will be given at each visit, and participants will not know which one they receive. * Participants will perform the same concentration and memory tasks at each testing visit, and will provide a blood sample after each visit to determi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-10-24 |
| Est. Completion | 2014-12-24 |
What the finished NCT01240616 record still lists
NCT01240616 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01240616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01240616 about?
NCT01240616 is a clinical study titled "Nicotinic Modulation of the Default Network of Resting Brain Function". Background: \- A brain circuit called the default network is the brain circuit that is active when the brain is at rest; that is, when individuals are not concentrating on specific tasks. Previous research has shown that the default network functions differently in people with schizophrenia and Alz...
What is the current status of trial NCT01240616?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2010-10-24. Estimated completion is 2014-12-24.
Who is sponsoring clinical trial NCT01240616?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI